This project intends to conduct a multicenter retrospective study to evaluate the satisfactory reduction of advanced ovarian cancer using PET-CT images, and explore the correlation between molecular biological characteristics and clinical characteristics of ovarian cancer through high-throughput sequencing genomics combined with radiomics.
Pathological type is epithelial ovarian cancer.
Underwent primary debulking surgery at our hospital.
Postoperative pathological staging is FIGO stage IIB or above.
Clinical, surgical, and pathological data of the patient are mostly complete.
Pathological type is non-epithelial ovarian cancer.
Underwent fertility-preserving surgery or palliative surgery.
Presence of infection during PET/CT image acquisition.
Concurrent other malignant tumors.
A total of 96 patients with advanced ovarian cancer who underwent PET-CT examination before the surgery, and received primary debulking surgery at our center from July 2017 to April 2024 were included for model development. Additionally, 50 patients from Zhejiang Cancer Hospital were included for model validation.
Cohort
Retrospective
Radio-score
Diagnostic testA score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
R0 resection
In patients with advanced ovarian cancer, the residual status after initial cytoreductive surgery is defined as follows: complete resection is defined as R0 resection, whereas visible residual tumor lesions during surgery are defined as non-R0 resection
5-year progression-free survival (PFS)
PFS was calculated from the date of the last chemotherapy until disease progression or death due to any cause.
5-year overall survival (OS)
OS was calculated from the date of the primary debulking surgery until death due to any cause.
Response to platinum-based chemotherapy
After the last chemotherapy, treatment efficacy was assessed according to NCCN guidelines. For primary tumor, patients who relapsed 6 months or more after initial chemotherapy were termed platinum-sensitive. In contrast, patients whose disease recurred in less than 6 months were classified as platinum-resistant.
Click on the lead sponsor to view all of their trials.
